Potential New Lead Compounds for the Treatment of Depression and Anxiety Disorders

Summary: Study identifies potential new drugs that can help treat depression and anxiety disorders without many of the adverse effects of other medications currently under evaluation.

Source: Medical University of Vienna

Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs confer benefits, they are also associated with adverse side-effects.

Conseqeuntly, medical researchers continuously thrive to improve the pharmacological properties of therapeutic agents to optimize the benefit-to-side-effect ratio. The research group led by Harald Sitte at the Center for Physiology and Pharmacology of the MedUni Vienna has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric disorders.

Importantly, the lead compounds displayed reduced risk of drug abuse and other adverse effects when compared to other agents that are currently under evaluation.

The research results were recently published in the journal Molecular Psychiatry.

In their preclinical experiments, the research team, led by Harald Sitte from the Institute of Pharmacology at MedUni Vienna’s Center for Physiology and Pharmacology, identified the potential of certain substances from the family of synthetic cathinone compounds for the treatment of mental illnesses.

Cathinones are derived from cathine, which is found in the khat plant, and are known for their ability to release monoamines such as noradrenaline, dopamine and serotonin.

“These substances first showed serotonin-related effects in our cell models, and then also in our mouse model,” says Harald Sitte, referring to this messenger substance that is considered to be a key factor in the drug treatment of depression and anxiety disorders such as social phobias or post-traumatic stress disorder.

The cathinone compounds used in the study attracted the scientists’ attention due to their preference for releasing serotonin without significantly increasing the dopamine level in the brain’s “reward centre”.

“Consequently, the new drugs we are researching are less likely to be abused and are also associated with fewer adverse effects overall,” emphasises Harald Sitte.

Serotonin release with less risk

Mental illnesses such as depression and anxiety disorders can be alleviated by increasing extracellular serotonin levels in the brain. This is usually achieved by substances that are classified as antidepressants.

The mode of action of these so-called selective serotonin reuptake inhibitors (SSRIs) is based on blocking the reuptake of serotonin from the synaptic cleft (neuronal interspace), which increases the amount of serotonin in the extracellular space.

This shows a depressed looking woman looking out a window
Mental illnesses such as depression and anxiety disorders can be alleviated by increasing extracellular serotonin levels in the brain. Image is in the public domain

Of note, “classical” antidepressants inhibit and “block” the serotonin transporter.

In contrast, recent evidence from preclinical and clinical studies identified the potential of drugs that elicit the release of serotonin via the serotonin transporter, i.e. substances that invert the natural transport direction of the serotonin transporter.

However, the serotonin-releasing agents currently undergoing clinical trials carry the risk of abuse and harmful side effects  such as MDMA, also known as “ecstasy,” which is taken as a “party drug” in non-clinical settings.

“Our research identified the first representatives of a new serotonin-releasing class of drugs that do not produce various adverse effects,” says study leader Harald Sitte, summarising the results of the study, which was conducted by first authors Felix Mayer (Florida Atlantic University) and Marco Niello (Center for Physiology and Pharmacology at MedUni Vienna) in collaboration with Vienna University of Technology, Florida Atlantic University, Peking University and the National Institute of Drug Abuse in Baltimore.

About this psychopharmacology research news

Author: Karin Kirschbichler
Source: Medical University of Vienna
Contact: Karin Kirschbichler – Medical University of Vienna
Image: The image is in the public domain

Original Research: Open access.
Serotonin-releasing agents with reduced off-target effects” by Harald Sitte et al. Molecular Psychiatry


Serotonin-releasing agents with reduced off-target effects

Increasing extracellular levels of serotonin (5-HT) in the brain ameliorates symptoms of depression and anxiety-related disorders, e.g., social phobias and post-traumatic stress disorder.

Recent evidence from preclinical and clinical studies established the therapeutic potential of drugs inducing the release of 5-HT via the 5-HT-transporter. Nevertheless, current 5-HT releasing compounds under clinical investigation carry the risk for abuse and deleterious side effects.

Here, we demonstrate that S-enantiomers of certain ring-substituted cathinones show preference for the release of 5-HT ex vivo and in vivo, and exert 5-HT-associated effects in preclinical behavioral models.

Importantly, the lead cathinone compounds (1) do not induce substantial dopamine release and (2) display reduced off-target activity at vesicular monoamine transporters and 5-HT2B-receptors, indicative of low abuse-liability and low potential for adverse events.

Taken together, our findings identify these agents as lead compounds that may prove useful for the treatment of disorders where elevation of 5-HT has proven beneficial.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.
  1. 5-htp potently releases serotonin with zero activity at post synaptic dopamine receptors or any transporters.

  2. MDMA is not addictive and in June 2021, in an article was out published in the NUMBER # 1 Ranked medical journal, Nature Med. This article which was multi-center, randomized, placebo controlled said trial
    concluded that MDMA should be brought to the point of care as quickly as possible and why did the 40+ PhDs publish this in Nature Med? It is the hardest peer reviewed journal in the world and they knew the uphill battle by remarks made in your article which are, “canned” responses to any mention of any substance on the US or UNDOCs list of Level 1 controlled substances. It is unprofessional, inaccurate, and leads people to believe that there is no use in MDMA. MDMA is harmful when mistakes are made in the sythsis of the molicule by street chemists. If done correctly under pharmaceuticals conditions, the byproducts of bad sythsis such as the switching off your thermal homeostasis mechanisms are indeed harmful. So, never take MDMA from the street but as the journal pointed out the people who stayed in the project for completion, many lost the definition of PTSD completely. They were effectively cured. You show me any other substance that can say that and I’ll eat s fish eyeball. In Asia, it’s a normal thing.

Comments are closed.